1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62EC9F78BC719A70100258ADA0025F394
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-rare-disease-field-medical-excellence-latam-mena-establishing-standards-high-performance-impact?opendocument
18
19opendocument
2034.236.191.0
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Field Medical Excellence

Benchmarking Rare Disease Field Medical Excellence in LATAM and MENA: Establishing Standards for High Performance & Impact

ID: 5798


Features:

9 Info Graphics

23 Data Graphics

170+ Metrics

7 Narratives


Pages/Slides: 38


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Benchmarking Rare Disease Field Medical Excellence in LATAM and MENA: Establishing Standards for High Performance & Impact”

STUDY OVERVIEW

The Latin America (LATAM) and Middle East/North Africa (MENA) regions present unique challenges and opportunities in the rare disease market, shaped by diverse healthcare systems, economic conditions, and cultural nuances. Optimizing the efficiency of field medical teams is paramount for rare disease manufacturers seeking to flourish in these markets.

Best Practices, LLC undertook this benchmarking research to establish standards for high field medical performance and impact in the LATAM and MENA regions' rare disease markets. Our study provides strategic insights tailored to boost KOL interactions, assess MSL performance, and strategically align staffing footprints.


KEY TOPICS

  • Effective Rare Disease Field Performance Metrics in the LATAM and MENA Regions
  • Building a Rare Disease Field Medical Excellence Framework
  • Target and Engagement Levels of Rare Disease KOLs in the LATAM and MENA Regions
  • Average Time Spent by Rare Disease MSLs on KOL Interactions and Internal Activities in the LATAM and MENA Regions
  • Rare Disease Field Medical Staffing Footprint in the LATAM and MENA Regions
  • Key Insights and Lessons Learned for Measuring the Impact of Rare Disease MSLs in the LATAM and MENA Regions

KEY METRICS

  • LATAM and MENA field scorecard: Benchmarking rare disease engagements
  • Average number of tiered vs. non-tiered KOLs per rare disease MSL in the LATAM and MENA regions
  • Monthly KOL and F2F interactions in the LATAM and MENA regions – Rare disease segment
  • Weighting criteria for various interaction types on the rare disease MSL scorecard (LATAM and MENA regions)
  • Metrics for engaging non-tiered KOLs in the LATAM and MENA regions
  • Average rare disease MSL time in the field (days per year) in the LATAM and MENA regions
  • Percentage of rare disease MSL time spent on external, internal, and logistics activities (LATAM and MENA regions)
  • Weekly rare disease MSL time allocation for each activity stream in the LATAM and MENA regions
  • Percentage of overall rare disease targets classified as KOLs, HCPs, payers, or other external stakeholders (LATAM and MENA regions)
  • Rare disease field medical staffing footprint in the LATAM and MENA regions

SAMPLE KEY FINDINGS

  • Time Spent on External Engagement: In LATAM, rare disease MSLs allocate a significant portion of their time (68%) to external engagement, surpassing other therapeutic areas. Conversely, in MENA, rare disease MSLs devote just over half of their time (55%) to direct external engagement efforts.

METHODOLOGY

Best Practices, LLC collated performance data and insights from field medical executives from rare disease companies around the world through a custom benchmark survey. Focused on rare disease field medical operations
in the LATAM and MENA regions, the research drew insights from a diverse range of respondents.

Best Practices, LLC also leveraged its propriety Field Medical Excellence database to provide additional benchmarks for maximal alignment with varied portfolio considerations.

The final study draws on 448 survey responses, representing a benchmark class of over 100 biopharma manufacturers.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biopharmaceutical; Manufacturing; Biotech; Consumer Products; Medical Device; Chemical; Clinical Research; Laboratories


Companies Profiled:
Abbott; AbbVie; Alexion Pharmaceuticals; Alkermes; Astellas; AstraZeneca; Bayer; BioMarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Clovis Oncology; CSL Behring; Curis; Daiichi Sankyo; Dermavant Sciences; Dompé; Eisai; Eurofarma; Exact Sciences; Galapagos; GE Healthcare; Genentech; Gilead Sciences; GlaxoSmithKline ; Grünenthal; Horizon Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Kyowa Kirin; Lundbeck; Merck; Merck KGaA; Merus; Novartis; Novo Nordisk; OM Pharma; Orchard Therapeutics; Pfizer; Radius Health; Inc.; Sanofi; Seres Therapeutics; Servier; Sunovion; Supernus; Takeda Pharmaceuticals; Teva Pharmaceutical Industries Ltd; UCB Pharma; Ultragenyx; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.